# Residual Solvents in Drug Products Marketed in the United States:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/residual-solvents-in-drug-products-marketed-in-the-united-states-guidance-for-industry/2d91b105-6b2c-4231-bcff-63a0d7fdc832

> FDA guidance document: Residual Solvents in Drug Products Marketed in the United States:  Guidance for Industry. Issue date: November 25, 2009. Get complete insights and analysis.

---

## Details

- Title: Residual Solvents in Drug Products Marketed in the United States:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2009-11-25
- Last Changed: 2020-04-23
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2008-D-0413">FDA-2008-D-0413</a>

## Related Documents

- [Individual Product Bioequivalence Recommendations for Specific Products](https://www.globalkeysolutions.net/guidances/guidance-document/individual-product-bioequivalence-recommendations-for-specific-products/321fabfb-8008-4b1d-856f-9a2e7d5e26b1)
- [End-of-Phase 2A Meetings](https://www.globalkeysolutions.net/guidances/guidance-document/end-of-phase-2a-meetings/05202b67-ba5f-49de-b49a-1f5466adf224)
- [Labeling OTC Human Drug Products; Small Entity Compliance Guide:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/labeling-otc-human-drug-products-small-entity-compliance-guide-guidance-for-industry/3f5cd376-fd4d-4e8f-9dee-98aab670f72f)